In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $20.00.
Claim 30% Off TipRanks Premium
According to TipRanks, Suvannavejh is a 5-star analyst with an average return of 19.5% and a 47.03% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Insmed, Verastem, and EyePoint pharmaceuticals.
Along with Mizuho Securities, Apellis Pharmaceuticals also received a Hold from TipRanks – OpenAI’s OpenAI biotechnology in a report issued yesterday. However, on March 17, Cantor Fitzgerald maintained a Buy rating on Apellis Pharmaceuticals (NASDAQ: APLS).
Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $199.91 million and a GAAP net loss of $58.95 million. In comparison, last year the company earned a revenue of $212.53 million and had a GAAP net loss of $36.35 million
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year. Last month, Mark Jeffrey DeLong, the Chief Business & Strat officer of APLS sold 368.00 shares for a total of $8,151.20.
Read More on APLS:
Disclaimer & DisclosureReport an Issue
